leisure time -WSS

leisure time

author：explore 2025-09-27 12:55:21 - browse：872

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Biden launches a new push to limit health care costs

WSS

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Why 40% Americans with Parkinson’s don’t see a neurologist

Death of patient in Alzheimer’s trial raises question of possible risks

California’s proposed $25 per hour health care minimum wage

Study: Pain burden is higher in Black NFL players than white ones

New research casts further doubt on a common procedure used with IVF

Wikipedia

leisure time

hotspot

In age of alternative facts, a scholarly course on calling out crap

NIH fellows want a pay raise. Will that mean less money for grants?

Guidelines to prevent youth baseball injuries need more muscle

Elizabeth Holmes on track for early release from her 11

Novavax promises a turnaround & Lilly roils the obesity market

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Moonlake's readout produced a cash windfall. Risks remain

Disclosing genetic information: not as worrisome as once feared

The cancer drug shortage isn’t new — and neither are the solutions

Charles Manson follower Leslie Van Houten released from prison after 53 years

knowledge

HCA discloses massive data breach affecting 11 million patients

STAT's guide to the next generation of CAR

What to know about OceanGate, the company behind the missing Titanic submersible

Retired US general questions alleged Putin, Prigozhin meeting

The battle over the Brookhaven Landfill on Long Island

What would happen to your eyes if you looked at the solar eclipse?

focus

hotspot

entertainment

focus